Safety and Efficacy Study of a Non-antibiotic Treatment for the Eradication of Helicobacter Pylori

Phase 1

Terminated

Brief Summary: At present, triple therapy is recommended by various guidelines for the treatment of Helicobacter pylori (H.pylori) infection. Recent studies have shown increasing resistance of H.pylori to commonly used antibiotics used in triple therapy. This study explores a non-antibiotic treatment regime for H.pylori that uses lauric acid as the primary anti-microbial agent. The study hypothesis is that Lauric acid works synergistically with omeprazole following administration of a mucolytic agent to kill H.pylori topically in the stomach.

Recruitment & Eligibility

Inclusion Criteria

Informed Consent prior to any study procedure
Age at least 21 years and up to 70 years
If female of childbearing potential who is sexually active, agrees to use acceptable methods of birth control throughout the study. Acceptable methods of birth control are: hormonal contraceptives (birth control pills), intrauterine device (IUD), diaphragm with spermicide, condom, vasectomy.

Additional Inclusion Criteria for Initial Phase only

Healthy volunteers - can have gastrointestinal or other symptoms if these do not require medical treatment and are considered by the investigator to be clinically minor and irrelevant to the conduct of the study.
Positive laboratory serology for H.pylori
Positive Urea Breath Test for H.pylori
Willing to undergo two gastroscopy procedures

Additional Inclusion Criteria for Secondary Phase only

Either healthy volunteers or patients attending gastroenterology outpatient clinic - can have gastrointestinal or other symptoms if these are considered by the investigator to be clinically minor or irrelevant to the conduct of the study.
Positive diagnosis of current H.pylori infection, as diagnosed by positive Urea Breath Test and at least one of the following: 1) Positive laboratory serology for H.pylori, 2) known positive Campylobacter-like organism (CLO) test or H.pylori culture from a gastroscopy performed in the 1 year prior to Screening.

Exclusion Criteria

Pregnant or breast feeding.
Clinically significant gastric disease, in the opinion of the investigator.
Significant disease or disorder on general medical examination, in the opinion of the investigator (general, respiratory, cardiovascular, renal, hepatic, neurological, bleeding tendency etc).
Regular or intermittent use of antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), anticoagulants or antiplatelet medications is expected during the trial period.
Cessation of proton pump inhibitor or H2-blocker therapy for 2 weeks prior to Urea Breath Test is likely to not be in the best interests of the participant.
Laboratory values on blood testing that are outside of the laboratory normal range and considered clinically relevant by the investigator: the following will be screened Haemoglobin (Hb), bilirubin, aspartate transaminase (AST), alanine transaminase (ALT), serum albumin, Alkaline Phosphatase, Urea, sodium (Na), potassium (K), creatinine (CRE).
Any contraindication to treatment with omeprazole, N-acetyl cysteine (NAC), or sodium bicarbonate.
Any evidence of organic or psychiatric disorders likely to result in poor compliance in the opinion of the investigator.
Previous participation in this trial at any time, or participation in any other clinical trial within the previous 3 months.

Arm && Interventions

Group	Intervention	Description
Treatment with GT08	GT08	Initial phase - omeprazole, N-acetyl cysteine (NAC), lauric acid dose and duration titration from 1 up to 14 days of treatment. Secondary phase - 14 days treatment with omeprazole, NAC, lauric acid

Primary Outcome Measures

Name	Time	Method
Number of Participants With Eradication of H.Pylori Infection	4-6 weeks following treatment	Eradication as measured by negative Urea Breath Test 4-6 weeks following completion of treatment
Absence of Significant Gastric Abnormality Post-treatment (Initial Phase)	up to 14 days of treatment	Gastroscopy pre- and post-treatment will be performed in the Initial Phase (20 participants), with the goal of excluding significant gastric abnormality at baseline and after treatment (e.g. gastric ulceration arising following the treatment).

Secondary Outcome Measures

Name	Time	Method
Assessment of Adverse Events (AE)	AE commencing within 30 days of initiation of treatment, followed until resolution	Adverse event data will be collected in response to neutral questioning.